# PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy

> **NCT07014215** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Anhui Provincial Cancer Hospital** · enrollment: 52 (estimated)

## Conditions studied

- NSCLC (Advanced Non-small Cell Lung Cancer)
- Resistance to Immunotherapy

## Interventions

- **DRUG:** Sintilimab combined with Bevacizumab and tafolecimab

## Key facts

- **NCT ID:** NCT07014215
- **Lead sponsor:** Anhui Provincial Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06
- **Primary completion:** 2027-05
- **Final completion:** 2029-05
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2025-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07014215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07014215, "PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT07014215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*